news
FDA clears NeuroXT's AI tool predicting Alzheimer's risk from MRIs
NeuroXT received FDA clearance for NEXT-Cue, an AI platform that combines standard brain MRIs with cognitive test scores to assess Alzheimer's risk in patients with mild cognitive impairment. The tool gives neurologists a quantitative progression readout without requiring invasive lumbar punctures or costly $5,000 PET scans. It turns routine imaging into an early warning system when brain interventions can still alter the timeline.
NeuroXT received FDA clearance for NEXT-Cue, an AI platform that combines standard brain MRIs with cognitive test scores to assess Alzheimer's risk in patients with mild cognitive impairment. The tool gives neurologists a quantitative progression readout without requiring invasive lumbar punctures or costly $5,000 PET scans. It turns routine imaging into an early warning system when brain interventions can still alter the timeline.
The architecture take
Getting an early Alzheimer's warning used to mean an expensive PET scan or an invasive lumbar puncture. NeuroXT just got FDA clearance for NEXT-Cue, software that calculates dementia progression risk by pairing standard brain MRIs with routine cognitive test scores. I used to dismiss AI radiology add-ons as Silicon Valley vaporware. I changed my mind after watching clinicians struggle to tell benign forgetfulness from early neurodegeneration in thirty-minute clinic visits. The algorithm flags subtle hippocampal volume loss and cortical shrinkage before gross memory failure sets in. Speed changes patient options. If you catch mild cognitive impairment early, lifestyle levers like zone 2 cardio, deep sleep protection, and tight glucose control actually have a fighting chance. What I watch closely now is how private longevity clinics bundle this into their $5,000 whole-body scans. Traditional neurology moves slow (often waiting six months for specialist referrals), but private cash-pay clinics will probably license this by autumn.